Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168974 | 0.85 | GABRA1 (0.79) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL4231409 | 0.84 | GABRA1 (0.71) | GABRA1GABRB2AKR1B1HSP90AA1KMT2A | |
| SCHEMBL11124585 | 0.80 | GABRA1 (0.51) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL11119579 | 0.80 | GABRA1 (0.51) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL2318046 | 0.80 | HSP90AA1 (0.49) | GABRA1GABRB2AKR1B1HSP90AA1KMT2A | |
| SCHEMBL248573 | 0.79 | PNMT (0.56) | GABRA1GABRB2AKR1B1MAPTALDH1A1 | |
| SCHEMBL836026 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL30817860 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL1258090 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2AKR1B1KMT2AMEN1 | |
| SCHEMBL346369 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2AKR1B1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130583-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20080319102-A1 | Dental Composition Containing Epoxy Functional Polymerizable Compounds | 3M DEUTSCHLAND GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080051488-A1 | Dental Composition Containing Unsaturated Halogenated Aryl Alkyl Ether Components | 3M DEUTSCHLAND GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051488-A1 | Dental Composition Containing Unsaturated Halogenated Aryl Alkyl Ether Components | 3M DEUTSCHLAND GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051488-A1 | Dental Composition Containing Unsaturated Halogenated Aryl Alkyl Ether Components | 3M DEUTSCHLAND GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1776079-A1 | DENTAL COMPOSITION CONTAINING EPOXY FUNCTIONAL POLYMERIZABLE COMPOUNDS | 3M Espe AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1765262-A1 | DENTAL COMPOSITION CONTAINING UNSATURATED HALOGENATED ARYL ALKYL ETHER COMPONENTS | 3M Espe AG (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005364-A1 | DENTAL COMPOSITION CONTAINING UNSATURATED HALOGENATED ARYL ALKYL ETHER COMPONENTS | 3M ESPE AG (DE) | 2006-01-19 | — | — | WO | disclosed |
| WO-2006005365-A1 | DENTAL COMPOSITION CONTAINING EPOXY FUNCTIONAL POLYMERIZABLE COMPOUNDS | 3M ESPE AG (DE) | 2006-01-19 | — | — | WO | disclosed |
| US-4924021-A | Cyclic phenol organosilanes and method for their preparation | HUELS AKTIENGESELLSCHAFT (DE) | 1990-05-08 | — | — | US | disclosed |
| EP-0132651-A2 | Use of cyclic phenol organosilane ester | HÜLS AKTIENGESELLSCHAFT (DE) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | GABRA1 2617/4885GABRB2 2762/4885AKR1B1 136/4885 |
| US-20080051488-A1 | Dental Composition Containing Unsaturated Halogenated Aryl Alkyl Ether Components | DDX3X, TAS2R39, TAS1R1 | GABRA1 610/4885GABRB2 1964/4885AKR1B1 1849/4885 |
| US-20080319102-A1 | Dental Composition Containing Epoxy Functional Polymerizable Compounds | EPX, TAS2R30, TAS2R31 | GABRA1 317/4885GABRB2 1375/4885AKR1B1 1654/4885 |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | KMO, KYNU, AADAT | GABRA1 2617/4885GABRB2 2762/4885AKR1B1 136/4885 |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | GABRA1 2617/4885GABRB2 2762/4885AKR1B1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.